15 results on '"Levent Ozsari"'
Search Results
2. Bone mineral density and fracture status of differentiated thyroid cancer patients under TSH suppression treatment
- Author
-
Dilek Gogas Yavuz, Yazan Ceyda Dincer, Zeliha Hekimsoy, Kadriye Aydin, Naile Gokkaya, Canan Ersoy, mge Aydogan Berna I, Aysen Akalin, Omercan Topaloğlu, Dilekci Esra Nur Ademoglu, Guven Baris Cansu, Bulent Can, Kagan Gungor, Mehtap Evran, Lezzan Keskin, Ziynet Alphan Uc, Ozlem Iyidir, Levent Ozsari, Tayfun Garip, Gulsah Elbuken, Meral Mert, Zafer Pekkolay, Zeynep Canturk, Can Ilgin, Nilufer Ozdemir Kutbay, Goknur Yorulmaz, Ahmet Toygar Kalkan, Unsal Yasemin Aydoğan, Adnan Yay, Barış Karagun, and Evin Bozkur
- Subjects
General Medicine - Published
- 2023
3. Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
- Author
-
Mouhammed Amir Habra, Sai-Ching J. Yeung, Mong-Hong Lee, Maria Angelica Cortez, Lance Pagliaro, Roeland Verhaak, Siyuan Zheng, Marie-Claude Hofmann, Levent Ozsari, Gilbert J. Cote, Camilo Jimenez, Tao Hai, Christopher G. Wood, Kanishka Sircar, Guermarie Velazquez-Torres, Weixin Wu, Enrique Fuentes-Mattei, and Liem M. Phan
- Abstract
Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
- Published
- 2023
4. Supplementary Figures S1-S6 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
- Author
-
Mouhammed Amir Habra, Sai-Ching J. Yeung, Mong-Hong Lee, Maria Angelica Cortez, Lance Pagliaro, Roeland Verhaak, Siyuan Zheng, Marie-Claude Hofmann, Levent Ozsari, Gilbert J. Cote, Camilo Jimenez, Tao Hai, Christopher G. Wood, Kanishka Sircar, Guermarie Velazquez-Torres, Weixin Wu, Enrique Fuentes-Mattei, and Liem M. Phan
- Abstract
High MET expression in ACC patients (S1); High MET mRNA expression levels in ACC (S2); cMET signaling is activated in ACC (S3); Increased HGF/cMET signaling is associated with enhanced proliferation and reduced apoptosis in tumors from ACC patients (S4); HGF stimulates NCI-H295R ACC cell proliferation (S5); HGF/cMET signaling is important for ACC cell energy metabolism (S6).
- Published
- 2023
5. Supplementary Tables S1-S12 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
- Author
-
Mouhammed Amir Habra, Sai-Ching J. Yeung, Mong-Hong Lee, Maria Angelica Cortez, Lance Pagliaro, Roeland Verhaak, Siyuan Zheng, Marie-Claude Hofmann, Levent Ozsari, Gilbert J. Cote, Camilo Jimenez, Tao Hai, Christopher G. Wood, Kanishka Sircar, Guermarie Velazquez-Torres, Weixin Wu, Enrique Fuentes-Mattei, and Liem M. Phan
- Abstract
Basic patients characteristics of the cohort used for serum HGF measurements ; Patients characteristics of second TMA ; Genes with significantly (P {less than or equal to} 0.05, absolute value of log ratio > 0.1) changed expression in tumors from ACC patients (dataset GSE10927) relative to expression in normal adrenocortical tissues ; Biological processes Significantly (P 0.1) changed in tumors from ACC patients with high MET expression compared to those with low MET expression (dataset GSE10927) ; Gene set enrichment analysis of ACC patients' cohort for genes related to cell proliferation (dataset GSE10927) ; Gene set enrichment analysis of ACC patients' cohort for genes related to the negative regulation of cell apoptosis (dataset GSE10927) ; Gene set enrichment analysis of ACC patients' cohort for genes related to cell proliferation (dataset GSEA49278) ; Gene set enrichment analysis of ACC patients' cohort for genes related to the negative regulation of cell apoptosis (dataset GSEA49278) ; Drug metabolism-related genes with significantly (P {less than or equal to} 0.05, absolute value of log ratio > 0.1) changed expression in tumors from ACC patients (dataset GSE10927) with high MET expression relative to those with low MET expression ; Gene set enrichment analysis detail of ACC patients' cohort for genes associated with resistance and metabolism of cisplatin, etoposide and doxorubicin (dataset GSEA10927) ; Gene set enrichment analysis detail of ACC patients' cohort for genes associated with resistance and metabolism of cisplatin, etoposide and doxorubicin (dataset GSEA49278) .
- Published
- 2023
6. Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients
- Author
-
Dilek Gogas Yavuz, Ceyda D. Yazan, Zeliha Hekimsoy, Kadriye Aydin, Naile Gokkaya, Canan Ersoy, Aysen Akalın, Omercan Topaloglu, Berna I. Aydogan, Esra N. A. Dilekci, Ziynet Alphan Uc, Guven B. Cansu, Levent Ozsari, Ozlem T. Iyidir, Mehtap E. Olgun, Lezzan Keskin, Meral Mert, Bulent Can, Kaan Gungor, Tayfun Galip, Zeynep Cantürk, Gulsah Elbuken, Zafer Pekkolay, Nilufer O. Kutbay, Goknur Yorulmaz, Ahmet T. Kalkan, Yasemin A. Unsal, Adnan Yay, Baris Karagun, Evin Bozkur, and YAVUZ D., Yazan C. D., Hekimsoy Z., Aydin K., Gokkaya N., ERSOY C., AKALIN A., Topaloglu O., Aydogan B. I., Dilekci E. N. A., et al.
- Subjects
Internal Diseases ,Endokrin ve Otonom Sistemler ,ENDOCRINOLOGY & METABOLISM ,CARCINOMA ,Endocrinology, Diabetes and Metabolism ,Endocrinology and Metabolic Diseases ,levothyroxine ,Sağlık Bilimleri ,Endokrinoloji ,GUIDELINES ,THERAPY ,İç Hastalıkları ,Clinical Medicine (MED) ,thyroid ,thyrotropin ,Endocrinology ,Hypothyroidism ,related ,Health Sciences ,Yaşam Bilimleri ,hormones/related ,thyroid cancer ,THYROXINE ,Humans ,Klinik Tıp (MED) ,Thyroid Neoplasms ,OUTCOMES ,Internal Medicine Sciences ,Klinik Tıp ,hormones ,Endocrine and Autonomic Systems ,thyroid function tests ,Life Sciences ,Dahili Tıp Bilimleri ,THYROTROPIN SUPPRESSION ,CLINICAL MEDICINE ,Tıp ,Cross-Sectional Studies ,Endokrinoloji ve Metabolizma Hastalıkları ,ENDOKRİNOLOJİ VE METABOLİZMA ,Medicine ,Endokrinoloji, Diyabet ve Metabolizma - Abstract
Thyroid-stimulating hormone (TSH) suppression treatment can induce signs and symptoms of hyperthyroidism and hypothyroidism due to inappropriate treatment or poor compliance to the treatment. The current study aimed to investigate TSH levels, frequency of being on target TSH, adherence to levothyroxine (LT4) suppression treatment in differentiated thyroid cancer (DTC) patients after surgery in a multicentric setting.This multicentric cross-sectional study was conducted at 21 medical centres from 12 cities in Turkey. DTC patients followed at least one year in the same center included in the study. Clinical data, serum TSH, free thyroxine (FT4), thyroglobulin (Tg) and anti-Tg levels were recorded during the most recent visit. Body mass index, systolic and diastolic blood pressures, pulse rate were measured. LT4 doses were recorded and doses per kilogram of bodyweight were calculated. Pill ingestion habits recorded and adherence to the therapy were evaluated using the Morisky Medication Adherence Scale and categorized as good, moderate or poor compliant based on their scores. Risk stratification forpredicting the disease persistance and/or reccurence was assessed using the American Joint Committee on Cancer-7th edition thyroid cancer staging calculator. TSH serum concentrations were classified as severe suppression (TSH lt; 0.01 mU/L), moderate suppression (TSH: 0.01-0.1 mU/L), mild suppression (TSHL 0.1-0.5 mU/L), euthyroid (TSH: 0.5-4 mU/L) and hypothyroid (TSH gt; 4 mU/L). TSH levels can also be classified as on being on target, under the target, or beyond over the target, according to the American Thyroid Association recommendations.A group of 1125 patients (F/M: 941/184, 50.7 ± 11.7 years) were included in the study. The mean LT4 daily dosage was 132.4 ± 39.6 mcg/day. TSH levels showed severe suppression in 99 (%8.8) patients, moderate suppression in 277 (%24.6) patients and mild suppression in 315 (%28) patients and euthyroid range in 332 (%29.5) patients and hypothyroid range in 97 (8.6%). TSH levels were in target in 29.2% of the patients 20.4% of the patients were undertreated, 50.4% overtreated. The daily LT4 dose and LT4 dose/kg were significantly higher in the severe suppression group (p lt; .001, p lt; .001). According to the Morisky scale, 564 patients (50.1%) were good compliant, 368 patients (32.7%) were moderate compliant, and 193 patients (17.1%) were noncompliant. Patients with poor compliance need a higher dose of LT4 compared to the good compliance group (p lt; .001). TSH levels of patients with good compliance were 0.67 ± 1.96 mU/L and TSH with poor compliance was 2.74 ± 7.47 mU/L (p lt; .001). TSH levels were similar in patients on fixed and alternating dosages.In 29.2% of the DTC patients, serum TSH levels were at target levels. Remaining of the study group have TSH levels under or over treatment range, exposing the patient to medication side effects. Majorty of the study group 82.8% have good or moderate adherence to LT4 therapy. Reaching TSH targets requires simplified and applicable guidelines and following the guideline recommendations.
- Published
- 2022
7. Refractory hypothyroidism: What else should be done?
- Author
-
Miray Yaman, Adnan Yay, Ferhat Deniz, Arif Yonem, Levent Ozsari, and Nursah Ozum
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,business ,Refractory (planetary science) ,Surgery - Published
- 2020
8. Even in Vitamin D Deficiency 1, 25 Dihydroxyvitamin D3 Level Is Normal in Pregnant Women
- Author
-
Arif Yonem, Aysen Ozkoral, Levent Ozsari, Pinar Kumru, Osman Metin Ipcioglu, Eylem Cagiltay, İsmet Gün, and Yaşam Kemal Akpak
- Subjects
medicine.medical_specialty ,business.industry ,Obstetrics and Gynecology ,030204 cardiovascular system & hematology ,medicine.disease ,vitamin D deficiency ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Reproductive Medicine ,Internal medicine ,medicine ,030212 general & internal medicine ,business - Abstract
Objectives: Vitamin D deficiency is a controversial issue in pregnant women. The 1,25 dihydroxyvitamin D3 level is higher in pregnant than non-pregnant women. This study aimed to investigate the 1,25 di-hydroxyvitamin D3 status in vitamin D deficient pregnant women at the first trimester. Materials and Methods: This study was conducted during December 2011 and April 2012 in 2 hospitals of Istanbul, Turkey. Pregnant women who attended for the regular examination on the 12th gestational week were randomly assigned. They were divided into 2 groups including vitamin D deficient (vitamin D
- Published
- 2018
9. Serum SIRT1 level is higher in male patient with isolated hypogonadotropic hypogonadism: The first study in human
- Author
-
Osman Metin Ipcioglu, Seyid Ahmet Ay, Kamil Baskoy, Seref Basal, Ebubekir Başpınar, Levent Ozsari, Yalcin Onem, Ferhat Deniz, Eylem Cagiltay, and Arif Yonem
- Subjects
0301 basic medicine ,Isolated hypogonadotropic hypogonadism ,medicine.medical_specialty ,business.industry ,Urology ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,Endocrinology ,Insulin resistance ,Reproductive Medicine ,Hypogonadotropic hypogonadism ,Internal medicine ,Androgen deficiency ,medicine ,business ,Body mass index ,hormones, hormone substitutes, and hormone antagonists ,Testosterone ,Homeostasis ,Hormone - Abstract
Objective Our aim is to compare the serum SIRT1 levels between patients with hypogonadotropic hypogonadism and healthy subjects. Material and method Twenty-five male patients diagnosed with isolated hypogonadotropic hypogonadism (IHH) and thirty healthy male as a control group were included in the study. Serum SIRT1, hormone levels and biochemical parameters, age, body mass index and insulin resistance were compared in both groups. Results Mean serum SIRT1 levels in patient and control group were 20.1 ± 11.7 ng/ml and 12.8 ± 7.1 ng/ml, respectively. Difference between both groups was statistically significant ( p = 0.02). The difference of Homeostasis Model Assessment-Insulin Resistance index (HOMA-IR) between two groups was also statistically significant. Patient group had more insulin resistance than the control group and it was statistically significant (mean HOMA-IR 2.66 ± 1.57 vs. 1.38 ± 0.43; p = 0.002). Conclusions This is the first human study that investigates SIRT1 levels and its relation with metabolic and hormonal parameters. We demonstrated that serum SIRT1 levels in patients with IHH were significantly higher than controls, and there is a negative correlation between testosterone and SIRT1 levels. The reason for elevated SIRT1 levels may be a compensation mechanism against both hypogonadotropic hypogonadism and insulin resistance. To understand the relation between SIRT1 and androgen deficiency, further large-scale randomized control studies are needed.
- Published
- 2017
10. Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study)
- Author
-
Guzin Fidan Yaylali, Faruk Kutluturk, Emre Bozkirli, Sait Gonen, Ilhan Satman, Sedat Cetin, Zafer Pekkolay, Demet Corapcioglu, Alper Sonmez, Sibel Guldiken, Zeliha Hekimsoy, Hamide Piskinpasa, Elif Bagdemir, Oguz Dikbas, Mustafa Kemal Balci, Hasan Aydin, T. Dogru, Mustafa Altay, Ilyas Capoglu, Amir Hassein Abedi, Mustafa Cesur, Serkan Yener, Erman Cakal, Guzide Gonca Oruk, Ibrahim Aslan, Ahmet Kaya, Elif Tutku Durmuş, Turkan Mete, Eylem Cagiltay, Berrin Çetinarslan, Belgin Efe, Irfan Nuhoglu, Eren Imre, Mehmet Eren, Sefika Dalkiran, Ozen Oz Gul, Mustafa Kutlu, Engin Güney, Esen Akbay, Ilhan Yetkin, Nur Kebapci, Serpil Salman, Volkan Yumuk, Kamile Gul, Canan Ersoy, Berrin Demirbas, Oguzhan Deyneli, Senay Topsakal, Yusuf Bozkus, Murat Yilmaz, Oguzhan Sitki Dizdar, Seda Sancak, Busra Yildiz, Feyza Yener Ozturk, Yuksel Altuntas, Fulya Turker, Ali Kirik, Ahmet Corakci, Cem Barçın, Rifki Ucler, Tevfik Sabuncu, Sibel Ertek, Bekir Cakir, Ibrahim Demirci, Fahri Bayram, Halil Onder Ersoz, Muge Ozsan Yilmaz, Nevin Dinccag, Mustafa Araz, Okan Yildiz, Levent Ozsari, Hatice Ozisik, Sule Canlar, Murat Dağdeviren, Cemile Idiz, B. Tamer Tetiker, Mehmet Asik, Safak Akin, Mesut Ozkaya, Zehra Capa, S. Nur Boysan, Ferit Kerim Kucukler, Alev Selek, Mustafa Ünübol, Cem Onur Kirac, Ozlem Haliloglu, Semra Ayturk, Ilker Cordan, Neslihan Bascil Tutuncu, Cem Haymana, Alpaslan Kemal Tuzcu, Ibrahim Sahin, Ramazan Cakmak, Pinar Sisman, Eren Gurkan, Basak Ozgen Saydam, Hulya Hacisahinogullari, Sinem Kiyici, Suleyman Nahit Sendur, Taner Bayraktaroglu, Didem Ozdemir, Emin Murat Akbas, Sazi Imamoglu, Ayse Carlioglu, Seher Çetinkaya Altuntaş, Şevki Çetinkalp, Kemal Agbaht, Aysegul Atmaca, Meral Mert, Suleyman Baldane, Gulhan Akbaba, Sonmez, A., Haymana, C., Bayram, F., Salman, S., Dizdar, O.S., Gurkan, E., Kargili Carlıoglu, A., Yeditepe Üniversitesi, Health Sciences University, Gulhane Faculty of Medicine, Department of Endocrinology and MetabolismAnkara, Turkey, Gulhane Training and Research Hospital, Department of Endocrinology and MetabolismAnkara, Turkey, Erciyes University, Faculty of Medicine, Department of Endocrinology and Metabolism, Kayseri, Turkey, Istinye University, Faculty of Medicine, Department of Endocrinology and Metabolism, Istanbul, Turkey, Kayseri Training and Research Hospital, Department of Endocrinology and Metabolism, Kayseri, Turkey, Mustafa Kemal University, Faculty of Medicine, Department of Endocrinology and Metabolism, Hatay, Turkey, Erzurum Training and Research Hospital, Department of Endocrinology and Metabolism, Erzurum, Turkey, Health Sciences University, Gulhane Faculty of Medicine, Department of CardiologyAnkara, Turkey, Harran University, Faculty of Medicine, Sanliurfa, Turkey, Istanbul University, Faculty of Medicine, Istanbul, Turkey, Trakya University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Corlu REYAP Private Hospital, Department of Endocrinology and Metabolism, Turkey, Canakkale 18 March University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Istanbul University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Istanbul University, Cerrahpasa, School of Medicine, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Fatih Sultan Mehmet Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Sultanabdulhamit Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, Marmara University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Istanbul Science University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Sisli Hamidiye Etfal Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, İstanbul Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, Yeditepe University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Private Office, Turkey, Uludag University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Bursa Sevket Yılmaz Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, Kocaeli University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Balikesir University, School of Medicine, Department of Internal Medicine, Turkey, Eskisehir Osmangazi University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Necmettin Erbakan University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Selcuk University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, Gulhane School of Medicine and Gulhane Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, Private Guven Hospital, Department of Endocrinology and Metabolism, Turkey, Gazi University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Ankara University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Hacettepe University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Yıldırım Beyazıt University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Ufuk University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Private Bayındır Hospital, Department of Endocrinology and Metabolism, Turkey, Baskent University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Diskapi Yildirim Beyazit Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, TOBB University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Private Memorial Hospital, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Kecioren Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, Erciyes University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Ege University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Izmir Ataturk Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, Dokuz Eylul University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Adnan Menderes University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Pamukkale University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Celal Bayar University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Mugla University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Antalya Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, Akdeniz University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Mersin University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Kahramanmaras Sutcu Imam University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Private Defne Hospital, Department of Endocrinology and Metabolism, Turkey, Mustafa Kemal University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Baskent University, Adana Training Hospital, Department of Endocrinology and Metabolism, Turkey, Cukurova University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, 19 Mayıs University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Samsun Training and Research Hospital, Department of Endocrinology and Metabolism, Turkey, Gaziosmanpasa University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Hitit University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Giresun University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Recep Tayyip Erdogan University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Karadeniz Technical University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Bulent Ecevit University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Kars Harakani State Hospital, Department of Endocrinology and Metabolism, Turkey, Inonu University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Erzincan University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Yuzuncu Yil University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Harran University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Dicle University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, University of Health Sciences, School of Medicine, Gaziantep Ersin Arslan Research and Training Hospital, Turkey, Gaziantep University, School of Medicine, Department of Endocrinology and Metabolism, Turkey, Çukurova Üniversitesi, Ege Üniversitesi, Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı, TOBB ETÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Demirbaş, Berrin, Zonguldak Bülent Ecevit Üniversitesi, Hitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Salman, Serpil, and Ondokuz Mayıs Üniversitesi
- Subjects
Blood Glucose ,Male ,obesity ,Glycated Hemoglobin A ,Turkey ,Turkish ,blood pressure measurement ,Endocrinology, Diabetes and Metabolism ,Type 2 diabetes ,Disease ,030204 cardiovascular system & hematology ,low density lipoprotein cholesterol ,0302 clinical medicine ,Endocrinology ,high density lipoprotein cholesterol ,Surveys and Questionnaires ,middle aged ,Medicine ,LDL-cholesterol ,glucose ,hemoglobin A1c ,education ,anthropometry ,exercise ,non insulin dependent diabetes mellitus ,adult ,clinical trial ,General Medicine ,health survey ,Europe ,female ,Type 1 diabetes ,risk factor ,diabetes mellitus ,language ,triacylglycerol ,medicine.medical_specialty ,insulin ,metabolic parameters ,hypertension ,HbA1c ,high performance liquid chromatography ,prevalence ,030209 endocrinology & metabolism ,immunoturbidimetry ,insulin dependent diabetes mellitus ,Article ,smoking ,03 medical and health sciences ,blood ,turkey (bird) ,Diabetes mellitus ,Internal medicine ,enzyme chemistry ,Internal Medicine ,cross-sectional study ,Humans ,controlled study ,human ,Glycemic ,glycosylated hemoglobin ,Glycated Hemoglobin ,business.industry ,questionnaire ,dyslipidemia ,medicine.disease ,major clinical study ,language.human_language ,body mass ,Blood pressure ,hypoglycemia ,glucose blood level ,multicenter study ,Cross-Sectional Studies ,Diabetes Mellitus, Type 2 ,Metabolic control analysis ,glycemic control ,Arterial blood pressure ,business ,metabolism - Abstract
Tutuncu, Neslihan Bascil/0000-0002-1816-3903; Gonen, Mustafa Sait/0000-0002-1089-623X; CORAPCIOGLU, DEMET/0000-0003-0940-9147; Satman, Ilhan/0000-0001-8613-1797; nuhoglu, irfan/0000-0003-0650-3242; Sahin, Ibrahim/0000-0002-6231-0034; Demirci, Ibrahim/0000-0003-0498-3115; Altuntas, Seher Cetinkaya/0000-0002-9733-9443; Yildiz, Bulent O./0000-0003-1797-7662; BALCI, Mustafa Kemal/0000-0002-6494-3249; Araz, Mustafa/0000-0001-6741-7474; Saydam, Basak Ozgen/0000-0001-9457-8919; Bozkus, Yusuf/0000-0002-6976-6659; Sabuncu, Tevfik/0000-0001-6504-5355; SELEK, ALEV/0000-0002-0646-8697; Ozturk, Feyza Yener/0000-0001-5584-4954; Salman, Serpil/0000-0003-4867-3725; AKBAS, EMIN MURAT/0000-0002-3033-0073; KIRIK, Ali Murat/0000-0002-5771-4843; Sonmez, Alper/0000-0002-9309-7715; Cesur, Fazil Mustafa/0000-0002-1029-2604, WOS:000452704800016, PubMed: 30244051, Aims: Turkey has the highest prevalence of diabetes in Europe. It is therefore essential to know the overall cardiovascular risk and reveal the predictors of metabolic control in Turkish adults with diabetes mellitus. Methods: A nationwide, multicenter survey consecutively enrolled patients who were under follow up for at least a year. Optimal control was defined as HbA1c, Turkish Society of Endocrinology and Metabolism, The TEMD study has been funded by the Turkish Society of Endocrinology and Metabolism. Automated blood pressure monitors were provided by Sanovel A/S. The funding agencies had no role in the design and conduct of the study; the collection, management, analysis and interpretation of the data; or the preparation, review or approval of the manuscript.
- Published
- 2018
11. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis
- Author
-
Jeffrey E. Lee, Mouhammed Amir Habra, Rena Vassilopoulou-Sellin, Kanishka Sircar, Naifa L. Busaidy, Rafael A. Vicens, Khaled M. Elsayes, Steven G. Waguespack, Mimi I. Hu, Merve Kutahyalioglu, Maria E. Cabanillas, Camilo Jimenez, Tarek Jazaerly, Levent Ozsari, and Ramona Dadu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Delayed Diagnosis ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Delayed diagnosis ,Malignancy ,behavioral disciplines and activities ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Hounsfield scale ,Adrenal Glands ,Adrenocortical Carcinoma ,medicine ,Humans ,Endocrine system ,Adrenocortical carcinoma ,Aged ,Aged, 80 and over ,Adrenal gland ,business.industry ,Cancer ,Adrenalectomy ,Middle Aged ,medicine.disease ,Adrenal Cortex Neoplasms ,stomatognathic diseases ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Radiological weapon ,Radiology ,business ,psychological phenomena and processes - Abstract
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy that is usually large (>5 cm) at time of diagnosis. Delayed diagnosis significantly worsens survival. We describe adrenal gland morphology prior to ACC diagnosis and discern potential causes of delayed diagnosis. ACC patients seen at The University of Texas MD Anderson Cancer Center between 1998 and 2014 who had cross-sectional body imaging ≥3 months prior to their diagnosis. We conducted a detailed review of clinical and radiological features in these patients prior to ACC diagnosis. Of 439 patients with ACC, 25 had imaging preceding ACC diagnosis (5 with normal adrenal glands and 20 with preexisting masses). On the first available images, the median mass size was 2.8 cm (range 0-9) with median precontrast density of 36 Hounsfield units (range 17-43) and became 9 cm (range 1-18) at the time of ACC diagnosis. The median interval between first available image and ACC diagnosis was 20 months (range 3-89). In the 5 patients whose initial images showed normal adrenal glands, the time between the last normal scan and ACC diagnosis ranged from 5 to 36 months. The most common reason for delayed ACC diagnosis was the presumed benign status of the preexisting mass (n = 13, 65 %). Radiologically suspicious adrenal masses can precede ACC diagnosis and have variable growth patterns. ACC can also develop de novo within a few months in a radiologically documented normal adrenal gland. The presumed benignancy of preexisting masses based on size is the main reason for delayed ACC diagnosis.
- Published
- 2015
12. Hepatocyte growth factor/cMET pathway activation enhances cancer hallmarks in adrenocortical carcinoma
- Author
-
Christopher G. Wood, Gilbert J. Cote, Camilo Jimenez, Levent Ozsari, Siyuan Zheng, Guermarie Velazquez-Torres, Weixin Wu, Mouhammed Amir Habra, Maria Angelica Cortez, Liem Phan, Mong Hong Lee, Lance C. Pagliaro, Enrique Fuentes-Mattei, Kanishka Sircar, Tao Hai, Roeland Verhaak, Marie Claude Hofmann, and Sai Ching J. Yeung
- Subjects
Male ,Cancer Research ,Angiogenesis ,Pyridines ,Mice ,Adrenocortical carcinoma ,Mitotane ,Anilides ,Molecular Targeted Therapy ,RNA, Small Interfering ,Aged, 80 and over ,Neovascularization, Pathologic ,Hepatocyte Growth Factor ,Middle Aged ,Proto-Oncogene Proteins c-met ,Neoplasm Proteins ,Gene Expression Regulation, Neoplastic ,Oncology ,Hepatocyte growth factor ,Female ,RNA Interference ,Cell Division ,medicine.drug ,Signal Transduction ,Adenoma ,Adult ,medicine.medical_specialty ,Mice, Nude ,Antineoplastic Agents ,Biology ,Article ,Internal medicine ,Cell Line, Tumor ,medicine ,Carcinoma ,Animals ,Humans ,Aged ,Cisplatin ,Cell growth ,Gene Expression Profiling ,Cancer ,medicine.disease ,Xenograft Model Antitumor Assays ,Adrenal Cortex Neoplasms ,Endocrinology ,Drug Resistance, Neoplasm ,Cancer research ,Transcriptome - Abstract
Adrenocortical carcinoma is a rare malignancy with poor prognosis and limited response to chemotherapy. Hepatocyte growth factor (HGF) and its receptor cMET augment cancer growth and resistance to chemotherapy, but their role in adrenocortical carcinoma has not been examined. In this study, we investigated the association between HGF/cMET expression and cancer hallmarks of adrenocortical carcinoma. Transcriptomic and immunohistochemical analyses indicated that increased HGF/cMET expression in human adrenocortical carcinoma samples was positively associated with cancer-related biologic processes, including proliferation and angiogenesis, and negatively correlated with apoptosis. Accordingly, treatment of adrenocortical carcinoma cells with exogenous HGF resulted in increased cell proliferation in vitro and in vivo while short hairpin RNA–mediated knockdown or pharmacologic inhibition of cMET suppressed cell proliferation and tumor growth. Moreover, exposure of cells to mitotane, cisplatin, or radiation rapidly induced pro-cMET expression and was associated with an enrichment of genes (e.g., CYP450 family) related to therapy resistance, further implicating cMET in the anticancer drug response. Together, these data suggest an important role for HGF/cMET signaling in adrenocortical carcinoma growth and resistance to commonly used treatments. Targeting cMET, alone or in combination with other drugs, could provide a breakthrough in the management of this aggressive cancer. Cancer Res; 75(19); 4131–42. ©2015 AACR.
- Published
- 2015
13. Multiple gestation in an essential thrombocythemia patient treated with interferon-alpha
- Author
-
Oral Nevruz, A. Ugur Ural, Levent Ozsari, Ümit Göktolga, and Ferit Avcu
- Subjects
Adult ,Pregnancy ,Essential thrombocythemia ,business.industry ,Platelet Count ,Pregnancy Complications, Hematologic ,Pregnancy Outcome ,Obstetrics and Gynecology ,Alpha interferon ,Interferon-alpha ,General Medicine ,medicine.disease ,Multiple Gestation ,Interferon α ,Immunology ,medicine ,Humans ,Female ,Pregnancy, Multiple ,business ,Thrombocythemia, Essential - Published
- 2007
14. Multikinase inhibitors use in differentiated thyroid carcinoma
- Author
-
Levent Ozsari, Mouhammed Amir Habra, and Sina Jasim
- Subjects
Sorafenib ,medicine.medical_treatment ,differentiated thyroid cancer ,Review ,lenvatinib ,Malignancy ,Targeted therapy ,Thyroid carcinoma ,chemistry.chemical_compound ,Rheumatology ,medicine ,Immunology and Allergy ,Pharmacology (medical) ,Progression-free survival ,Thyroid cancer ,business.industry ,Thyroid ,Gastroenterology ,targeted therapy ,medicine.disease ,3. Good health ,medicine.anatomical_structure ,Oncology ,chemistry ,Immunology ,adverse effects ,Cancer research ,sorafenib ,business ,Lenvatinib ,progression-free survival ,medicine.drug - Abstract
Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from traditional cytotoxic chemotherapy. In this review, we describe newly developed small-molecule tyrosine kinase inhibitors (TKIs) that are being actively tested and used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular targeted therapy is evolving based on understanding of the pathways involved in DTC. Disrupting tumor vascular supply by targeting vascular endothelial growth factor receptor signaling is the most commonly used approach to treat advanced/metastatic DTC. Other mechanisms include targeting BRAF, MAPK/ERK kinase, or mammalian target of rapamycin signaling. Although TKIs appear to have superior efficacy compared to cytotoxic chemotherapy, they can cause substantial adverse effects; symptomatic management of adverse effects, dose adjustment, or cessation of therapy may be required.
- Published
- 2014
15. Erratum to: Comparison of lymphomononuclear cell energy metabolism between healthy, impaired glucose intolerance and type 2 diabetes mellitus patients
- Author
-
G. Uckaya, Mustafa Kutlu, Hakan Boyunaga, Ali Uğur Ural, Nuri Karadurmus, Mustafa Sahin, Levent Kenar, and Levent Ozsari
- Subjects
medicine.medical_specialty ,Endocrinology ,medicine.anatomical_structure ,business.industry ,Endocrinology, Diabetes and Metabolism ,Internal medicine ,Cell ,medicine ,Energy metabolism ,Endocrine system ,Type 2 Diabetes Mellitus ,business - Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.